Barr Ellison Solicitors – commercial property
Advertisement: Mogrify mid banner
Advertisement: Excalibur Healthcare mid banner
Mid banner advertisement: BDO
Advertisement: Simpsons Creative
Advertisement: RSM mid banner
Advertisement: HCR Hewitsons recruitment mid banner
ARM Innovation Hub
Advertisement: EBCam mid banner
Advertisement: CJBS mid banner
Advertisement mid banner S-Tech 1
Advertisement: partnersand mid banner
Advertisement: Kao Data Centre mid banner
Advertisement: Cambridge Network mid banner
22 October, 2021 - 19:42 By Tony Quested

Inivata reveals clinical alliance with Canadian cancer centre

Inivata, a Cambridge-based leader in liquid biopsy, has agreed a clinical collaboration with the Princess Margaret Cancer Center in Toronto, Canada. The deal involves the use of Inivata’s liquid biopsy assays – InVisionFirst®-Lung and RaDaR™ – in two separate studies.

The Accelerating Lung Cancer Diagnosis through Liquid Biopsy, ACCELERATE, study plans to compare time to treatment initiation in advanced non-small cell lung cancer (NSCLC) patients who have had a liquid biopsy, versus those patients referred in the previous 12 months who were treated based on tissue profiling. 

The prospective, single-arm study will use Inivata’s InVisionFirst-Lung, a ctDNA next-generation sequencing (NGS) liquid biopsy, testing 37 genes relevant to the care of patients with advanced NSCLC.

It will assess the utility of blood-based NGS to accelerate time to treatment in patients awaiting their diagnostic tissue biopsy and molecular profiling. Patient recruitment has already started, with the aim to enrol 150 patients with advanced NSCLC over the next 12 months.

The second study, ctDNA Lung, will use Inivata’s RaDaR assay for ctDNA detection of minimal residual disease (MRD) to identify patients for curative therapy after lung cancer resection and will be split into two phases. 

The first phase, DETECT, will screen 360 early-stage lung cancer patients to assess the rate of pre- and post-operative ctDNA levels using RaDaR. 

Of the 360 patients, 66 participants with ctDNA detected at 3-6 weeks post-operatively will be referred to the second phase for a randomised controlled trial, RCT, investigating the benefit of intensified adjuvant treatment with chemo-immunotherapy.

Clive Morris, President of Inivata, said: “Inivata is committed to building a robust body of evidence to support the use of its innovative liquid biopsy technologies and we are delighted to be collaborating with the Princess Margaret Cancer Center, which is one of the largest and most prestigious cancer centres in the world. 

“The ctDNA lung trial is another important step in demonstrating the potential of our exceptionally sensitive RaDaR assay in the early detection of residual disease and informing treatment decisions which lead to better outcomes for patients.”

Dr. Natasha Leighl, Lung Site Lead, Medical Oncology, Princess Margaret Cancer Center, added: “Liquid biopsy technologies have the potential to transform cancer treatment, getting patients to the right treatment faster and increasing the chances of a cure. We look forward to working with Inivata on these important studies.”

Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Earlier this year, NASDAQ powerhouse NeoGenomics Inc exercised its right to hoover up the whole of Inivata, having made an initial $25 million minority investment. Florida-based NeoGenomics took up a fixed price option to buy the remainder for a further $390m in May 2021.

Newsletter Subscription

Stay informed of the latest news and features